Dr Swati Shah · Apollo Hospital, Bhat, Gandhinagar · Gota OPD, Ahmedabad
Shah’s Gastro, Cancer & Robotic Surgery Centre — trained at national cancer centres, fully qualified in surgical oncology, and operating on urological cancers every week.
Dr Swati Shah
MS, DrNB (Surgical Oncology)
Prostate Cancer Surgeon · Apollo Hospital, Bhat, Gandhinagar · Gota OPD, Ahmedabad
This page is for a man whose PSA has become detectable again after a radical prostatectomy, and for the family reading the report with him. It explains what the number means, what has to be confirmed before anything is started, when a PSMA-PET scan is worth its cost, and what salvage radiotherapy will and will not do to continence and to erections. It is written by Dr Swati Shah, Prostate Cancer Surgeon at Apollo Hospital, Bhat, Gandhinagar.
The situation is almost always the same. The operation went well. The first PSA after surgery was undetectable, and so was the next one, and the visits settled into a routine. Then a report comes back with a figure on it instead of the reassuring line the man had got used to. Nobody has said the word recurrence out loud yet, but everyone in the room has read it.
What follows here is the sequence Dr Swati Shah works through in that consultation, in the order she works through it. The order is the point. Men who are treated in this order do well; men who are given hormone injections first and investigated afterwards lose the one window in which this is still curable.
After a radical prostatectomy the PSA should be undetectable, below 0.1 ng/mL. A value of 0.2 ng/mL or above, confirmed on a repeat test and rising, is biochemical recurrence. It means prostate tissue is still producing PSA somewhere — most often in the prostate bed, sometimes in pelvic lymph nodes, less often further away.
The prostate and the seminal vesicles were removed at surgery. Nothing else in the body makes PSA in any quantity. So a measurable, rising PSA is not a laboratory quirk and it is not the bladder or the kidneys; it is prostate cancer cells, somewhere, still alive.
That sounds worse than it is. Biochemical recurrence is a chemical finding, detected long before anything can be seen on a scan and years before anything could be felt or would cause a symptom. It is the earliest possible warning, and that is exactly why it is treatable. A man in this position is not in the same situation as a man who presents with bone pain.
Two things separate a recurrence that can still be cured from one that cannot. The first is where the cells are: confined to the prostate bed and the pelvis, or already outside it. The second is time. Salvage treatment given while the PSA is still low works far better than the same treatment given a year later at a higher number, and the difference is not small.
Before any treatment is planned, the PSA is repeated in the same laboratory to confirm the rise is real, and at least two or three values over time are used to calculate the PSA doubling time. A single reading decides nothing. The doubling time, together with the original histology, decides how urgent this is.
Laboratories differ, assays differ, and a single unexpected figure is repeated before it is acted on. Once it is confirmed, the pattern of the numbers becomes the most useful information available — more useful, at this stage, than any scan.
A PSA that creeps up slowly over two years behaves very differently from one that doubles in three months. The first may never threaten the man’s life; the second needs treatment now. This is also where the original surgical histology comes back into the conversation: the ISUP grade group, whether the margin was positive, whether the seminal vesicles or the nodes were involved, and whether the report mentioned cribriform or intraductal patterns.
| Finding | What it usually indicates | What it changes |
|---|---|---|
| PSA stays below 0.1 ng/mL | No recurrence | Routine surveillance continues unchanged |
| Single value of 0.2 ng/mL or above | Unconfirmed — may be assay variation | Repeat in the same laboratory before acting |
| Confirmed and rising, slow doubling time | Usually disease confined to the prostate bed | Salvage radiotherapy to the bed, planned without panic |
| Confirmed and rising, short doubling time | Higher chance of disease outside the bed | Imaging and a multidisciplinary discussion urgently |
| Never became undetectable after surgery | Persistent disease, not a new recurrence | Different pathway — imaging first, treated as higher risk |
The distinction in the last row is missed often. A man whose PSA never fell to undetectable after the operation does not have biochemical recurrence; he has persistent disease, and he is managed differently from the outset.
A PSMA-PET/CT scan is worth doing once the PSA is above 0.2 ng/mL and only where the result will genuinely change the plan. Below that level the scan frequently finds nothing even when disease is present, and a falsely reassuring scan delays the treatment that would have worked.
PSMA-PET is the most sensitive imaging available for this disease and it has changed how recurrence is managed. It can show a single node in the pelvis that a CT scan would never have resolved, and it can show disease outside the pelvis that turns a planned course of local radiotherapy into a different conversation altogether.
It is also self-funded in Ahmedabad and it is not always available the same week, because the tracer supply depends on generator and cyclotron availability. Dr Swati Shah’s practice is to say what the scan costs at the moment it is ordered, not at the billing counter, and to order it only when the answer will change what is done next.
Where a family genuinely cannot fund it, a conventional bone scan with CT remains an acceptable alternative and treatment is not delayed while money is raised. That is a deliberate position: a man treated promptly on conventional imaging does better than a man whose salvage radiotherapy waited three months for a scan.
For most men with biochemical recurrence after surgery, the curative treatment is radiotherapy to the prostate bed, given while the PSA is still low. This is called early salvage radiotherapy, and the evidence is consistent that it is better to start it at a low PSA than to wait and watch the number climb.
The prostate has already been removed, so this is not radiotherapy to the prostate; it is radiotherapy to the bed where the prostate used to sit, and often to the pelvic lymph nodes as well. It is delivered as a course of outpatient treatments by a radiation oncologist, and a surgeon who tells a man that radiotherapy is the lesser option is doing him a disservice.
The one thing that must be said plainly is what it costs in function. A man who has already had a prostatectomy has spent the last year or two rebuilding his continence and, if the nerves were spared, his erections. Radiotherapy on top of surgery compounds both. Urinary irritation and urgency are common during and after the course; some men find their pad use increases again, and a proportion of that does not return to where it was. Erectile function declines further, and the decline after radiotherapy is gradual rather than sudden, appearing over months.
None of this is a reason to decline treatment. It is a reason to hear it before consenting rather than afterwards, and to have the pelvic floor physiotherapy and the penile rehabilitation restarted alongside the radiotherapy rather than after it.
Androgen deprivation therapy is added to salvage radiotherapy in selected men — typically those with a short PSA doubling time, adverse histology or node-positive disease — and it is not given routinely to every man with a rising PSA. Hormone therapy alone, without radiotherapy, does not cure biochemical recurrence.
This is the commonest error in the management of a rising PSA in Indian practice: a hormone injection is started, the PSA obediently falls, everyone is reassured, and the window for curative salvage radiotherapy closes quietly in the background. The falling number feels like success. It is not.
Where hormone therapy is genuinely indicated it is given for a defined period alongside radiotherapy, and its own consequences are managed from day one rather than discovered later. Androgen deprivation causes bone loss, weight gain, loss of muscle, disturbed sugars and low mood, and in men who already have diabetes or heart disease those are the things most likely to shorten their lives. Before it is started Dr Swati Shah checks cardiovascular risk, fasting sugars and lipids, blood pressure, vitamin D and bone density, and arranges bone protection where it is needed.
Intermittent hormone therapy is a reasonable option in biochemical recurrence, which is not true in advanced metastatic disease. That difference matters to a man’s quality of life over years.
If a PSMA-PET scan shows disease confined to one or two pelvic lymph nodes, the case is discussed in a multidisciplinary meeting before anything is done. Options include radiotherapy covering the pelvic nodes, systemic treatment, and in carefully selected men a salvage lymph node dissection.
Node-only recurrence is the situation PSMA-PET created. It was invisible before, so it was never treated specifically. It is now visible, and the right answer is genuinely not settled — which is exactly why it goes to a multidisciplinary meeting rather than to one surgeon’s preference.
Dr Swati Shah’s position is stated openly with the man in the room. Salvage lymph node surgery after a previous pelvic operation and possible radiotherapy is technically demanding, the tissue planes are scarred, and it is not offered as a routine. Where it is offered, it is offered as part of a plan that includes systemic treatment, not as a stand-alone cure, and the man is told that before he agrees to it.
Recovery from salvage treatment is measured in three things that are recorded at every visit: the PSA, the pad count and erectile function. If they are not written down they are not managed, and Indian men will not raise the last two on their own.
The response to the late effects described above is active, not passive. Pelvic floor physiotherapy is restarted and supervised, not handed over as a leaflet. Penile rehabilitation continues. If heavy leakage persists beyond a year after everything has finished, that is a decision point, not a reason to keep waiting — a sling or an artificial urinary sphincter is discussed at that stage rather than years later.
Alongside that, the PSA is followed. A PSA that falls to undetectable after salvage radiotherapy and stays there is the result everyone is working for, and many men get it.
★★★★★
“Dr. Swati Shah performed my prostate surgery, and I am truly grateful for her care and expertise. It has been 3 years since the operation, and I recently visited for a follow-up. I am doing well now and living a normal, healthy life. Thank you so much, doctor, for your excellent treatment and support.”
Kiran Parikh · Google review, Apollo Hospital, Bhat
★★★★★
“I’m so grateful to Dr. Swati Shah for her care during prostate cancer treatment. She was professional, caring, and very patient in answering all my questions. Her thorough approach and confidence gave me peace of mind. Excellent surgeon and wonderful person!”
DIVYA PARMAR · Google review, Apollo Hospital, Bhat
★★★★★
“Dr. Swati Shah operated on my father for prostate cancer. The surgery was successful and his recovery is going well. She explained everything clearly and treated us with great care and patience. Very thankful to her and her team. Highly recommended.”
Dhruv Maheta · Google review, Gota clinic
From the first consultation to the end of salvage treatment, the pathway runs through five stages. Most men complete the first two within a fortnight of making contact, and the whole sequence is planned around the fact that starting early is what makes it work.
Salvage radiotherapy is outpatient treatment and does not usually need admission. Apollo Hospital, Bhat is empanelled with the major insurers and with Ayushman Bharat, and pre-authorisation is handled by the hospital’s own team before treatment starts.
What moves the estimate most is the imaging, whether pelvic nodes are included in the radiotherapy field, and whether hormone therapy is part of the plan and for how long. PSMA-PET is self-funded and is the single item families most often do not expect; its cost is quoted at the time it is ordered.
Send your policy details along with the reports and pre-authorisation is started in parallel with the medical planning rather than after it. For families funding treatment themselves, the estimate is given in writing once the plan is fixed, and the alternatives are laid out where a cheaper investigation gives an adequate answer.
Not by definition. Biochemical recurrence after surgery is a confirmed value of 0.2 ng/mL or above that is rising. A figure below that is repeated and watched rather than treated, and the trend over the next few tests is what matters.
Usually not. At this stage the commonest site is the prostate bed itself. Bone involvement is what imaging is for, and at a low PSA it is uncommon.
Almost never as the first move. Hormone therapy lowers the number without curing the disease, and starting it first can close the window for salvage radiotherapy, which can. It is added to radiotherapy in selected men, not used instead of it.
It is essential when the result will change the plan, and not otherwise. Below a PSA of 0.2 ng/mL it often shows nothing even when disease is present. Where it cannot be funded, a bone scan and CT are used and treatment goes ahead.
It can. Most men notice urgency and frequency during the course, which settles, and some find their pad use increases again afterwards. This is discussed in full before consent, and pelvic floor physiotherapy is restarted alongside the treatment.
Many men can. Salvage radiotherapy given early, while the PSA is low and the disease is still in the prostate bed, is given with curative intent, and a PSA that falls to undetectable and stays there is a realistic goal.
Yes. Bring the operation notes and the histology report with the PSA series. Where the operation was done changes nothing about what is decided now.
Dr Swati Shah I Robotic Uro Oncologist I Prostate, Kidney, Bladder Cancer specialist
Gota, Ahmedabad, Gujarat
Directions to the Gota clinic
Dr Swati Shah Uro Oncologist I Prostate, Bladder, Kidney Cancer I Robotic surgeon
Apollo Hospital, Bhat, Gandhinagar, Gujarat
Directions to Apollo Hospital, Bhat
Telephone and WhatsApp: +91 63590 11009
Dr Swati Shah consults at the Gota OPD in Ahmedabad and operates at Apollo Hospital, Bhat, Gandhinagar. Men travelling from Saurashtra, north Gujarat and Rajasthan are usually able to complete the consultation and the tests in a single visit if they call ahead.
A PSA that has started to climb after a radical prostatectomy is not a relapse of the whole disease, and it is not an emergency. It is a signal with a clock attached. Treated early it is very often still curable; treated late it usually is not. This page explains what the number means, which scan is worth paying for, and why the timing of salvage treatment matters more than which centre does it. Call +91 63590 11009 WhatsApp Dr Swati Shah's team
Swasth Parivar: twice a month, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
